Diamyd Medical (DMN) Stock Overview
Develops precision medicine therapies for the treatment of autoimmune diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DMN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Diamyd Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.075 |
| 52 Week High | SEK 1.80 |
| 52 Week Low | SEK 0.054 |
| Beta | 2.29 |
| 1 Month Change | -4.91% |
| 3 Month Change | 6.94% |
| 1 Year Change | -91.84% |
| 3 Year Change | -90.26% |
| 5 Year Change | -97.58% |
| Change since IPO | -89.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.4% | -2.1% | 1.5% |
| 1Y | -91.8% | 7.2% | 3.1% |
Return vs Industry: DMN underperformed the German Biotechs industry which returned 7.8% over the past year.
Return vs Market: DMN underperformed the German Market which returned 4.1% over the past year.
Price Volatility
| DMN volatility | |
|---|---|
| DMN Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: DMN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DMN's weekly volatility has decreased from 24% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 44 | Anders Essen-Möller | www.diamyd.com |
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.
Diamyd Medical AB (publ) Fundamentals Summary
| DMN fundamental statistics | |
|---|---|
| Market cap | €14.34m |
| Earnings (TTM) | -€25.88m |
| Revenue (TTM) | €39.41k |
Is DMN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMN income statement (TTM) | |
|---|---|
| Revenue | SEK 432.00k |
| Cost of Revenue | SEK 3.41m |
| Gross Profit | -SEK 2.97m |
| Other Expenses | SEK 280.67m |
| Earnings | -SEK 283.65m |
Last Reported Earnings
May 31, 2026
Next Earnings Date
Oct 07, 2026
| Earnings per share (EPS) | -1.83 |
| Gross Margin | -688.43% |
| Net Profit Margin | -65,659.03% |
| Debt/Equity Ratio | 0% |
How did DMN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/06 11:58 |
| End of Day Share Price | 2026/08/06 00:00 |
| Earnings | 2026/05/31 |
| Annual Earnings | 2025/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diamyd Medical AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maria Karlsson Osipova | DNB Carnegie Commissioned Research |
| Ludvig Svensson | DNB Carnegie Commissioned Research |